moneyheap
NRIX · Analysis updated Nov 5, 2026, 11:50 AM ET
Why is Nurix Therapeutics (NRIX) stock moving?
Nurix's fiscal Q3 was shaped by the Roche bexobrutideg collaboration. It brought $673.1M of revenue, mostly one-time license revenue, and $549.8M of net income. Cash rose to $1.1B, with runway into the second half of 2029. The EPS of $4.73 missed consensus, but the revenue beat was large. The stock reacted mildly, falling about 2% after the report. The stock closed at $25.69 on Nov 2, near the upper part of its $11.67-$28.23 52-year range. The pipeline is advancing: the Phase 3 CLL trial has dosed its first patient, the NX-1607 expansion cohorts have started, and partners paid milestones of $7M and $10M. The company also dropped zelebrudomide to concentrate resources. Analyst targets of roughly $33-$41 sit above the current price. Main risks are clinical binary outcomes, dependence on partner payments, and non-recurring revenue that flatters earnings. Price and volume data were unavailable, so the technical picture could not be assessed.
News behind the analysis
- Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateDosed first patient in the Phase 3 DAYBreak CLL-306 trial of bexobrutideg. Cash is $1.1B after the $700M Roche upfront, with runway into the second half of 2029.
- Nurix Therapeutics falls 2% following Q3 earnings as operating expenses upQ3 revenue was $673.1M, including $653.2M of Roche license revenue and a $10M Sanofi milestone. G&A rose to $34.4M on one-time Roche deal costs.
- Nurix Therapeutics Q3 2026 Earnings: Results, Market Reaction & HistoryEPS of $4.73 missed the $5.11 consensus, while revenue of $673.1M beat the $479.5M estimate by 40%. The Roche license revenue is one-time.
- What Nurix Therapeutics Stock's Profit Turnaround Means For ShareholdersQ3 net income was $549.81M against a prior-year loss of $86.42M. Earnings depend heavily on large collaboration payments, so durability is the main risk.
- Nurix Therapeutics Earnings Q3 2026 - ReportThe company discontinued zelebrudomide to focus capital on bexobrutideg. The $1.1B in liquidity provides a roughly 3-year runway.
- Nurix Q3 2026 results (GlobeNewswire via Manila Times)Pfizer paid a $7M milestone, and Gilead extended a research term for a $10M fee. Sanofi started a Phase 1 trial of the STAT6 degrader.
- Nurix Therapeutics 2026 Company Profile: Stock PerformanceThe share price was $25.69 as of Nov 2, down from a prior close of $26.80. The 52-week range is $11.67-$28.23 and market cap is about $2.81B.
- Nurix Therapeutics (NRIX) Stock Price & OverviewSeveral analysts raised price targets, including Stifel to $41, Morgan Stanley to $38, and Baird and Wainwright to $36. Truist trimmed its target to $33.